The impact of blue light cystoscopy with hexaminolevulinate (HAL) on progression of bladder cancer - A new analysis

Bladder Cancer

Volumn 2, Issue 2, 2016, Pages 273-278

  Kamat, Ashish M ^a   Cookson, Michael ^b   Witjes, J Alfred ^c   Stenzl, Arnulf ^d   Grossman, H Barton ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Bladder cancer; Blue light cystoscopy; Hexaminolevulinate; NMIBC; Progression

Indexed keywords

EID: 85012064911     PISSN: 23523727     EISSN: 23523735     Source Type: Journal    
DOI: 10.3233/BLC-160048     Document Type: Article

References (22)

1. Lamm D, Persad R, Brausi M, et al. Defining progression in nonmuscle invasive bladder cancer: It is time for a new, standard definition. J Urol 2014;191:20-7.
2. Grossman HB, Stenzl A, Fradet Y, et al. Long-term reduction in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012;188:58-62.
3. Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with non-muscle invasive bladder cancer. J Urol 2010;184:1907-13.
4. Daniltchenko D, Riedl CR, Sachs MD, et al. Longterm benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005;174:2129-33.
5. Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000;163:60-1.
6. LebretT, Bohin D, Kassardjian Z, et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol 2000;163:63-7.
7. van der Meijden A, Sylvester R, Collette L, Bono A, ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: A combined analysis of 5 European Organization for Research and Treatment of Cancer trials. J Urol 2000;164: 1533-7.
8. Sylvester RJ, van der Meijden AP, Witjes JA, et al. Highgrade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005;66:90-107.
9. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163:73-8.
10. May M, Brookman-Amissah S, Roigas J, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: A multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 2010;57:850-8.
11. Cao D, Vollmer RT, Luly J, et al. Comparison of 2004 and 1973 World Health Organization grading systems and their relationship to pathologic staging for predicting long-term prognosis in patients with urothelial carcinoma. Urology 2010;76:593-9.
12. Chade DC, Shariat SF, Godoy G, et al. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol 2010;184:74-80.
13. Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: A prospective, phase III multicenter study. J Urol 2005;174:862-66.
14. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: A phase III, multicenter study. J Urol 2007;178:68-73.
15. Jichlinski P, Guillou L, Karlsen S, et al. Hexyl aminolevulinate fluorescence cystoscopy: A new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol 2003;170:226-29.
16. Zaak D, Kriegmair M, Stepp H, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: Results of 1012 fluorescence endoscopies. Adult Urol 2001;57:690-4.
17. Schmidbauer J, Witjes F, Schneller M, Donat R, Susani M, Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171:135-38.
18. Burgués JP, Conde G, Oliva J, et al. Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: Experience of the BLUE group. Actas Urol Esp 2011;May 26.
19. Grossman HB, Gomella L, Fradet Y, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:62-7.
20. Burger M, Grossman HB, Droller MJ, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis of detection and recurrence based on raw data. Eur Urol 2013;http://dx.doi.org/10.1016/j.eururo.2013.03.059.
21. Gakis G, Ngamsri T, Rausch S, et al. Fluorescence-guided bladder tumour resection: Impact on survival after radical cystectomy. World J Urol 2015;2015. doi:10.1007/s00345-015-1485-8
22. Geavlete B, Multescu R, Georgescu D, Jecu M, Stanescu F, Geavlete P. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: Does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int 2012;109:549-56.